Business
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials Canada Ne...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Jan. 20, 2020\n\n\n\nVANCOUVER, Jan. 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid  cannabinol (\"CBN\") as the active pharmaceutical ingredient (\"API\") in its two product candidates under development: INM-755 for epidermolysis bullosa (\"EB\") and INM-088 for glaucoma. InMed is leading the way in the clinical development of CBN to treat human disease.\n\n \n \n\n \n\"We are proud to be the first company to investigate cannabinol's therapeutic potential in human clinical trials,\" commented InMed CEO, Eric A. Adams. \"InMed has completed more than 30 preclinical pharmacology and toxicology studies, identifying potential therapeutic advantages of CBN in specific disease models over the more common cannabinoids THC and CBD, as well as other rare variants.\" Mr. Adams continued, \"We are simultaneously exploring innovative biosynthetic manufacturing methods and therapeutic applications of CBN formulations to target diseases with high unmet medical need.\" \nInMed's scientific team today officially revealed CBN as the API in INM-755 at the EB2020 World Congress in London, UK, where they will also exhibit preclinical data in support of the INM-755 program in EB. \nINM-755 is being developed as InMed's lead dermatological product candidate for the treatment of symptoms related to EB, a rare genetic skin disease characterized by fragile skin that can lead to extensive wounds and blistering. INM-755 is formulated as a CBN-based topical cream. In addition to relief of symptoms, including inflammation and pain, InMed believes INM-755 may enhance skin integrity in a subset of EB Simplex patients. Following regulatory and ethics committee approval in December 2019, InMed initiated a Phase 1 clinical trial for INM-...